Whitepaper
6 Oct 2020
Enabling Commercial Manufacturing for Highly Complex Small Molecule Drugs through Process Engineering and Technological Innovation
-file109336.JPG)
PDF 145 kB
Content provided by our supplier
BioVectra Inc.
-
CA -
2015On CPHI since
-
2Certificates
-
500 - 999Employees
Company types
Primary activities
Other Content from BioVectra Inc. (2)
-
News BioVectra to build Canada's first mRNA vaccine and biomanufacturing facility
The state-of-the-art centre will be built in Prince Edward Island to support domestic biomanufacturing capabilities -
-file109124.JPG)
Video BioVectra's CDMO Capabilities
BioVectra offers contract development and manufacturing capacity for intermediates and active pharmaceutical ingredients (APIs) from five North American cGMP facilities. We specialize in Microbial Fermentation, Complex Chemistry, Biologics, and Formulation Development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance